What this study looked at
This meta-analysis examined whether psychedelic-assisted therapy is associated with changes in suicidality by analyzing individual patient data from multiple clinical trials.
Who participated
• Participants across several clinical trials involving psychedelic-assisted therapy
• Included individuals with depression and other mental health conditions
• Data combined at the individual patient level
Key findings
• Significant reductions in suicidality were observed after psychedelic therapy
• Improvements were often seen alongside reductions in depression symptoms
• Effects appeared across different psychedelic compounds and study designs
• No evidence of increased suicidality related to treatment in these trials
What this suggests
Psychedelic-assisted therapy may reduce suicidal thoughts in clinical populations, particularly when delivered in structured and supportive environments.
Why clinical context matters
These findings come from controlled settings with screening, preparation, and integration. Outcomes may differ outside of these conditions.
Important limitations
• Limited number of trials and sample sizes
• Variation in study designs and populations
• Long-term effects on suicidality are still being studied
Bottom line for AURA responses
Psychedelic therapy may help reduce suicidality in clinical settings. AURA should emphasize that this research is emerging and that treatment occurs under careful supervision.